Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

Fotios Loupakis; Chiara Cremolini; Lisa Salvatore; Marta Schirripa; Sara Lonardi; Vanja Vaccaro; Federica Cuppone; Diana Giannarelli; Vittorina Zagonel; Francesco Cognetti; Giampaolo Tortora; Alfredo Falcone; Emilio Bria

doi:10.1002/cncr.26460

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

Cancer ◽

10.1002/cncr.26460 ◽

2011 ◽

Vol 118 (6) ◽

pp. 1523-1532 ◽

Cited By ~ 30

Author(s):

Fotios Loupakis ◽

Chiara Cremolini ◽

Lisa Salvatore ◽

Marta Schirripa ◽

Sara Lonardi ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Monoclonal Antibodies ◽

Growth Factor ◽

Growth Factor Receptor ◽

Clinical Impact ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

702 PUBLICATION Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80997-8 ◽

2005 ◽

Vol 3 (2) ◽

pp. 199

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3512 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3512-3512 ◽

Cited By ~ 4

Author(s):

J. M. Tabernero ◽

E. Van Cutsem ◽

J. Sastre ◽

A. Cervantes ◽

J.-L. Van Laethem ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3535 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3535-3535 ◽

Cited By ~ 42

Author(s):

E. Díaz Rubio ◽

J. Tabernero ◽

E. van Cutsem ◽

A. Cervantes ◽

T. André ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-07-1053 ◽

2008 ◽

Vol 14 (1) ◽

pp. 215-223 ◽

Cited By ~ 19

Author(s):

G. Folprecht ◽

J. Tabernero ◽

C.-H. Kohne ◽

C. Zacharchuk ◽

L. Paz-Ares ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Irreversible Inhibitor ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

Oncology ◽

10.1159/000453336 ◽

2017 ◽

Vol 92 (4) ◽

pp. 205-212 ◽

Cited By ~ 2

Author(s):

Hiroko Hasegawa ◽

Hiroya Taniguchi ◽

Seiichiro Mitani ◽

Toshiki Masuishi ◽

Azusa Komori ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer

Cancer ◽

10.1002/cncr.22851 ◽

2007 ◽

Vol 110 (4) ◽

pp. 752-758 ◽

Cited By ~ 28

Author(s):

Maria Giulia Zampino ◽

Elena Magni ◽

Cristian Massacesi ◽

Alberto Zaniboni ◽

Angelo Martignetti ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Orally Active ◽

First Line Treatment ◽

Receptor Inhibitor

Download Full-text

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3512 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3512-3512 ◽

Cited By ~ 24

Author(s):

J. M. Tabernero ◽

E. Van Cutsem ◽

J. Sastre ◽

A. Cervantes ◽

J.-L. Van Laethem ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3644 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3644-3644 ◽

Cited By ~ 9

Author(s):

T. Seufferlein ◽

C. Dittrich ◽

J. Riemann ◽

E. Woell ◽

T. Herrmann ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer

Medicine ◽

10.1097/md.0000000000010097 ◽

2018 ◽

Vol 97 (10) ◽

pp. e0097 ◽

Cited By ~ 2

Author(s):

Datian Chen ◽

Li Li ◽

Xiang Zhang ◽

Guangyi Gao ◽

Lili Shen ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Journal of Clinical Oncology ◽

10.1200/jco.2016.70.2472 ◽

2017 ◽

Vol 35 (6) ◽

pp. 692-692 ◽

Cited By ~ 3

Author(s):

Young Hak Kim

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text